TW209832B - - Google Patents

Download PDF

Info

Publication number
TW209832B
TW209832B TW079108480A TW79108480A TW209832B TW 209832 B TW209832 B TW 209832B TW 079108480 A TW079108480 A TW 079108480A TW 79108480 A TW79108480 A TW 79108480A TW 209832 B TW209832 B TW 209832B
Authority
TW
Taiwan
Prior art keywords
compound
group
methyl
isomer
stupid
Prior art date
Application number
TW079108480A
Other languages
English (en)
Chinese (zh)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB898922795A external-priority patent/GB8922795D0/en
Priority claimed from GB909012472A external-priority patent/GB9012472D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of TW209832B publication Critical patent/TW209832B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C07C215/32—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton containing hydroxy groups and carbon atoms of two six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW079108480A 1989-10-10 1990-10-09 TW209832B (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898922795A GB8922795D0 (en) 1989-10-10 1989-10-10 Chemical compounds
GB909012472A GB9012472D0 (en) 1990-06-05 1990-06-05 Chemical compounds

Publications (1)

Publication Number Publication Date
TW209832B true TW209832B (fr) 1993-07-21

Family

ID=26296026

Family Applications (1)

Application Number Title Priority Date Filing Date
TW079108480A TW209832B (fr) 1989-10-10 1990-10-09

Country Status (10)

Country Link
EP (1) EP0422889A3 (fr)
JP (1) JPH03133946A (fr)
KR (1) KR100192622B1 (fr)
AU (1) AU629989B2 (fr)
CA (1) CA2027262A1 (fr)
IE (1) IE903614A1 (fr)
IL (1) IL95936A (fr)
NZ (1) NZ235605A (fr)
PT (1) PT95542B (fr)
TW (1) TW209832B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919827A (en) * 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
GB9215274D0 (en) * 1992-07-17 1992-09-02 Scras Derivatives of(phenylethyl-beta-ol)amine
ES2065269B1 (es) * 1993-05-11 1995-10-01 S A L V A T Lab Sa 6-(4-(fenilbutoxi) hexilaminometil-4-hidroxi-a1,a3-bencenodimetanol. procedimiento para la obtencion del mismo y nuevos intermedios utilizados en su preparacion.
WO1995015953A1 (fr) * 1993-12-10 1995-06-15 Ciba-Geigy Ag Nouvelles oxazolidines substituees
US6254882B1 (en) 1997-09-16 2001-07-03 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol
ZA994264B (en) 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
US7232837B2 (en) 1999-06-29 2007-06-19 Mcneil-Ppc, Inc. Stereoisomers with high affinity for adrenergic receptors
GB0014546D0 (en) 2000-06-14 2000-08-09 Glaxo Group Ltd A novel process
GB0105560D0 (en) * 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
PL1937626T3 (pl) * 2005-10-17 2016-08-31 Generics Uk Ltd Sposób i związki do otrzymywania salmeterolu
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
WO2009154557A1 (fr) 2008-06-18 2009-12-23 Astrazeneca Ab Dérivés de benzoxazinone agissant comme agoniste des récepteurs bêta2-adrénergiques pour le traitement de troubles respiratoires
WO2016142582A1 (fr) 2015-03-11 2016-09-15 Fermion Oy Procédé de préparation de salmétérol cristallin et de son sel de xinafoate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8310477D0 (en) * 1983-04-18 1983-05-25 Glaxo Group Ltd Chemical compounds
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
DE3806321A1 (de) * 1988-02-27 1989-09-07 Boehringer Mannheim Gmbh Neue trisubstituierte amine, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten

Also Published As

Publication number Publication date
CA2027262A1 (fr) 1991-04-11
EP0422889A2 (fr) 1991-04-17
AU629989B2 (en) 1992-10-15
NZ235605A (en) 1992-12-23
KR910007867A (ko) 1991-05-30
KR100192622B1 (ko) 1999-06-15
IE903614A1 (en) 1991-04-24
PT95542B (pt) 1999-09-30
EP0422889A3 (en) 1991-08-28
IL95936A (en) 1996-01-19
PT95542A (pt) 1991-08-14
IL95936A0 (en) 1991-07-18
AU6390190A (en) 1991-04-18
JPH03133946A (ja) 1991-06-07

Similar Documents

Publication Publication Date Title
TW209832B (fr)
TW201733B (fr)
TW470740B (en) Pharmaceutical compositions for synergistic treatment of Parkinsonism
CA1283122C (fr) Ethers de phenyl
US10988433B2 (en) Cyclohexyl GPR40 agonists for the treatment of type II diabetes
TWI225860B (en) Novel indolin-2-one derivatives, their preparation and the pharmaceutical compositions comprising them
CN110396085A (zh) 联合治疗
LU85856A1 (fr) Composes de phenethanolamine
US5468767A (en) Antidepressant 3-(aminocycloalkenyl)-indole-5-nitrile derivatives
EP0181793A1 (fr) Dérivés de pipéridine, leur préparation et leur application en thérapeutique
JP2008517897A (ja) 新規なジカルボン酸誘導体
CA2107566A1 (fr) Derives ethanolamine ayant des activites sympathomimetiques et anti-pollakiurie
JPS6059914B2 (ja) フエノ（アルコ）キシ−置換されたオキシランカルボン酸、その製法、その使用及びこれを含有する医薬品
JP5528524B2 (ja) 冷感剤及びｔｒｐｍ８活性化剤
IE50998B1 (en) Substituted oxiranecarboxylic acids,processes for their preparation,their use and medicaments containing them
CN101827828B (zh) 作为5-羟色胺能调节剂的1,2,4-三唑衍生物
CN104507898B (zh) 苯酚衍生物及其制备方法和在医药上的应用
EP0445749B1 (fr) Cyclopentènylamines N-monosubstituées, procédé pour leur préparation et leur emploi comme médicament
JPH05501554A (ja) ムスカリン様レセプター拮抗薬
Carter et al. Analogs of oxybutynin. Synthesis and antimuscarinic and bladder activity of some substituted 7-amino-1-hydroxy-5-heptyn-2-ones and related compounds
US10487058B2 (en) Cyclopropyl unsaturated quinoline compound used as leukotriene receptor antagonist and applications thereof
DK163182B (da) Dialkylaminoalkoxybenzylalkoholderivater og farmaceutisk acceptable syreadditionssalte og kvaternaere ammoniumsalte deraf, fremgangsmaade til fremstilling deraf, farmaceutisk praeparat og fremgangsmaade til fremstilling deraf
CN106278857A (zh) α,β‑不饱和羰基四氢萘酮衍生物及其应用
JPH03193747A (ja) ２―ヒドロキシ―３―フエノキシプロピルアミノ化合物、該化合物を含有する肥満症及び類縁症状の治療用薬剤学的組成物、該化合物の製造方法、及び中間体
TW412527B (en) Novel 4-diphenylmethyl piperidine derivatives